Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2011
Date:11/7/2011

t also on the longer-term commercial opportunities as we continue to develop this important product," continued Ms. Parshall.

"Although Kynamro is our flagship drug and will be the first systemic antisense drug to reach the market, our pipeline goes well beyond Kynamro.  Numerous drugs in our pipeline have demonstrated efficacy in early clinical studies and could represent significant commercial opportunities," continued Ms. Parshall. "The success of our drug discovery and development efforts is evident every quarter as we move our drugs closer to the market.  Already this year, we have initiated clinical studies on five drugs, reported encouraging data on our CRP drug and added new drugs into development to treat a wide variety of diseases.   We anticipate continuing this steady progress for the rest of the year and into 2012.

"Our business strategy is successful as evidenced by the growth of our partnered pipeline and the substantial cash from our partnering deals.  We benefit financially both in the near-term and long-term, from upfront fees, milestone payments, royalties and profit sharing payments and other types of commercial participation.  This year, we have earned $13 million in milestones and upfront payments from our partner, GSK, with the expansion of our collaboration to include a sixth target, initiation of clinical development on our TTR drug and identification of the next drug, ISIS-AATRx, to move into development.  This collaboration provides us with a knowledgeable partner and allows us to quickly expand our severe and rare disease franchise," concluded Ms. Parshall.  

Corporate and Drug Development Highlights

  • Dr. John Kastelein presented data from the mipomersen open-label extension study at the European Society of Cardiology Congress 2011.  These data, in patients who have been treated with mipomersen for greater than one year, demonstrated sustained reductions in
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
    2. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
    3. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
    4. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
    5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
    6. Cambrex Reports Third Quarter 2011 Results
    7. Dyadic International Reports 2011 Third Quarter Financial Results
    8. Rochester Medical Reports Fourth Quarter and Fiscal Year End Results
    9. Mettler-Toledo International Inc. Reports Third Quarter 2011 Results
    10. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
    11. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... KONG and FT LAUDERDALE, Florida ... Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative ... that on May 13, 2015, it prevailed in a final ... European Patent EP 1 341 482 - STENT HAVING HELICAL ... of review in the EPO and has been upheld as ...
    (Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, Inc. ... on the development and commercialization of proprietary compounded ... ring The Nasdaq stock market closing bell on ... growing success of its Go Dropless™ campaign since ... cataract procedures are performed annually in the U.S. ...
    (Date:7/1/2015)...  LabStyle Innovations Corp. (DRIO), developer of the ... of Todd Durniak as Senior Vice President and General ... over 20 years of medical device commercial and ... and General Manager of Neighborhood Diabetes, a division ... durable medical equipment (DME) and pharmacy channels with ...
    Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 2LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 3LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 4
    ... SILVER SPRING, Md., Oct. 7, 2011 The U.S. ... simvastatin), a fixed-dose combination (FDC) prescription medication that contains ... in adults who need both sitagliptin and simvastatin. ... million people in the United States have type 2 ...
    ... Oct. 7, 2011 ProteinSimple today announced plans ... service support for its biologics products in Europe, ... are included in this expanded support structure:  iCE ... systems. The biologics market segment is ...
    Cached Medicine Technology:FDA Approves Combination Therapy Juvisync 2FDA Approves Combination Therapy Juvisync 3ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe 2
    (Date:7/1/2015)... NJ (PRWEB) , ... July 01, 2015 , ... ... , the global cancer enterprise of Hospital Corporation of America (HCA), as it ... and research, OncLive announced today. , With this new partnership, OncLive’s editorial ...
    (Date:7/1/2015)... ... July 01, 2015 , ... Lisa Keys, the widow of U.S. Army Master ... Keys’ birthday) in memory of her late husband and all of America’s fallen military ... Bronze Star Medal, died during a Special Forces training exercise in December of 2012. ...
    (Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. is a ... white paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care ... at: http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group ...
    (Date:7/1/2015)... ... 01, 2015 , ... A Priority Setting Partnership put in ... list they hope will guide future mesothelioma research. Surviving Mesothelioma has just posted ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer the ...
    (Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... the top executive search firms in the healthcare industry, B. E. Smith has ...
    Breaking Medicine News(10 mins):Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3
    ... no reduced death risk in patients with localized disease, ... -- Oral sodium clodronate improves overall survival in advanced ... death in those with localized disease, British researchers say. ... more than 800 men enrolled in two trials launched ...
    ... , KENILWORTH, N.J., Aug. 11 Schering-Plough Corporation ... an antihistamine eye drop strong enough to control itchy eyes all day ... are sold, CLARITIN Eye works in minutes to relieve the itch of ... , To view the Multimedia News Release, go to: ...
    ... , WASHINGTON, Aug. 11 To gain an insider,s ... publisher of the Guide to Retirement Living SourceBook, will ... downtown Washington, D.C. retirement community. Gurney is documenting his experiences and ... the last 20 years, Gurney has immersed himself in the business ...
    ... , MOUNTAIN LAKES, N.J., Aug. 11 Today ... -- announces the "3 in 4 Need More" campaign to promote ... big hole in it," says Jonas Roeser, a founding member, "if it ... *(PHOTO 72dpi: Send2Press.com/mediaboom/09-0811-LTCG3in4_72dpi.jpg) , , *(Photo Caption/Cutline: ...
    ... CARY, N.C., Aug. 11 Cornerstone Therapeutics Inc. (Nasdaq: ... products primarily for the respiratory and related markets, today reported financial results for ... Recent Highlights: , , , ... or 78%, compared to 2008 , , ...
    ... , HERMOSA BEACH, Calif., Aug. 11 On ... committed to improving the quality of life for Latino children with cancer and ... the 2009 AVP CROCS SLAM BUD LIGHT ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090811/LA59829 ) , , In 2009, AVP named ...
    Cached Medicine News:Health News:Oral Drug Ups Survival in Advanced Prostate Cancer Cases 2Health News:Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours 2Health News:Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours 3Health News:Middle-Aged Senior Care Advocate to Move Into D.C. Retirement Community 2Health News:New Health Reform Campaign Will Support Long-Term Care for All, Because '3 in 4 Need More' 2Health News:New Health Reform Campaign Will Support Long-Term Care for All, Because '3 in 4 Need More' 3Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 2Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 3Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 4Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 5Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 6Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 7Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 8Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 9Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 10Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 11Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 12Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 13Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 14Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 2Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 3
    Inquire...
    Inquire...
    ... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
    ... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
    Medicine Products: